新型血液檢測提升結核病診斷準確度
New Blood Test Improves Tuberculosis Diagnosis
結核病（ㄊㄧㄝˊㄏㄜˊㄅㄧㄥˋ）仍是一項重大的全球健康挑戰，每年造成超過百萬人死亡。
Tuberculosis (TB) remains a major global health challenge, causing over a million deaths annually.
數十年來，診斷一直依賴「痰液檢測」（ㄊㄢˊㄧㄝˋㄐㄧㄢˇㄘㄜˋ）或「皮膚測試」（ㄆㄧˊㄈㄨㄘㄜˋㄕˋ），這些方法往往緩慢、難以執行，或無法區分潛伏性與活動性感染。
For decades, diagnosis has relied on "sputum-based tests"[0|18|26|type:method] or "skin tests"[27|38|type:method], which are often slow, difficult to administer, or unable to distinguish between latent and active infection.
然而，隨著研究人員開發出新型「血液檢測」，醫療領域正經歷顯著轉變。
However, a significant shift in the medical landscape is underway as researchers develop new "blood-based assays"[39|60|type:innovation].
這些創新檢測旨在克服舊有方法的限制，利用諸如「CRISPR基礎診斷」等先進技術，直接偵測血液中的細菌「游離DNA」（ㄧㄡˊㄌㄧˊDNA）。
These innovative tests aim to overcome the limitations of older methods by using advanced techniques like "CRISPR-based diagnostics"[61|87|type:technology] to detect bacterial "cell-free DNA"[88|103|type:biomarker] directly in the blood.
與目前的標準（例如「IGRA」）不同，這些新工具承諾能快速取得結果，通常在不到一小時內即可完成，這對於阻斷傳播至關重要。
Unlike current standards, such as the "IGRA"[104|108|type:test], these new tools promise rapid results, often in under an hour, which is crucial for stopping transmission.
透過擺脫複雜的樣本採集流程，這些快速的定點照護檢測可能成為全球「弱勢族群」的變革利器，幫助醫生更快採取行動以挽救生命。
By moving away from complex sample collection, these rapid, point-of-care tests could be a game-changer for "vulnerable populations"[118|140|type:group] worldwide, helping doctors act faster to save lives.
